Lupus-Like Syndrome Attributable to Anti-Tumor Necrosis Factor α Therapy in 14 Patients During an 8-Year Period at Mayo Clinic

Compared with previous studies, cutaneous findings were less frequent and arthritis was more frequent in our cohort of patients. Some patients were able to tolerate an alternative TNF-α inhibitor without recurrence of lupus-like syndrome.